Retatrutide vs Mounjaro: Are These the Same Thing?
If you’ve been searching for retatrutide and keep ending up on pages about Mounjaro, or you’ve seen the two drug names used interchangeably in social posts and forums, you’re not alone. The confusion is understandable: both are made by Eli Lilly, both treat similar conditions, and both are weekly incretin injections. But they are different drugs. Here’s what each one actually is, what makes them different, and why the confusion exists in the first place.
Retatrutide and Mounjaro are different drugs. Mounjaro is the brand name for tirzepatide, a dual agonist of GLP-1 and GIP receptors, approved by the FDA in 2022 for type 2 diabetes. Retatrutide is an investigational triple agonist of GLP-1, GIP, and glucagon receptors, currently in Phase 3 trials and not yet approved for any indication.
The short version: Mounjaro activates two receptors. Retatrutide activates three. Mounjaro is approved and on the U.S. market today. Retatrutide is not. Both are made by Eli Lilly, which is why their development histories run in parallel and why people keep confusing them.
What Mounjaro Actually Is
Mounjaro is the U.S. brand name for tirzepatide when it is prescribed for type 2 diabetes. Tirzepatide is a once-weekly subcutaneous injection developed by Eli Lilly. It was approved by the FDA in May 2022 for adults with type 2 diabetes.
Tirzepatide is a dual agonist: it activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GLP-1 receptor activation slows gastric emptying, promotes satiety, and stimulates insulin release in response to meals. GIP receptor activation also stimulates insulin release and appears to enhance the effects of GLP-1 in ways that are still being characterized.
When tirzepatide is prescribed for chronic weight management rather than for type 2 diabetes, it is sold under a different brand name: Zepbound. The molecule is the same; the brand and indication differ. This branding distinction is part of what creates confusion when people are searching online.
What Retatrutide Actually Is
Retatrutide (development code LY3437943) is an investigational once-weekly subcutaneous injection developed by Eli Lilly. As of May 2026, it is in Phase 3 clinical trials. It is not approved by the FDA, is not commercially available under any brand name, and cannot legally be prescribed for any indication.
Retatrutide is a triple agonist: it activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. The third receptor — glucagon — is what makes retatrutide structurally different from tirzepatide. Glucagon receptor activation contributes to increased energy expenditure and improved lipid metabolism, which is one of the proposed reasons retatrutide has produced deeper weight loss than tirzepatide in trials so far.
Understanding what retatrutide is starts with this three-receptor mechanism, because the added glucagon activity is the key pharmacologic difference separating it from Mounjaro’s tirzepatide.
The Phase 3 program for retatrutide is called TRIUMPH. The first successful Phase 3 readout (TRIUMPH-4 in adults with obesity and knee osteoarthritis) reported in December 2025 with a mean 28.7% body-weight reduction at the highest dose. The pivotal obesity trial (TRIUMPH-1) is expected to read out in 2026. For more, see our overview of what retatrutide is and how retatrutide works.
Why People Keep Confusing the Two
Three things drive the confusion.
Both are Eli Lilly drugs. They share a manufacturer, a scientific lineage, and similar mechanism categories. Lilly’s broader incretin portfolio also includes oral and combination products, which adds further variations on the theme.
Both are weekly subcutaneous injections. Patients describing their experience often use shorthand — ‘the weekly shot’ or ‘the GLP-1 drug’ — that doesn’t distinguish between the molecules. Online forums and social media frequently mix references to tirzepatide, semaglutide, retatrutide, and other drugs without specifying which one is being discussed.
The brand-versus-generic naming pattern is genuinely confusing. Tirzepatide is sold as Mounjaro in T2D and Zepbound in obesity. Retatrutide does not yet have a brand name because it is not approved. When retatrutide is approved, it will likely receive a brand name distinct from any of the existing Lilly products — adding yet another label to learn.
How They Differ in the Data
Direct head-to-head Phase 3 data between retatrutide and tirzepatide does not yet exist. The only retatrutide-vs-tirzepatide active-comparator trial — TRIUMPH-5 — is not expected to read out for some time. Cross-trial comparisons are necessarily rough, but they are what is currently available.
Tirzepatide in adults with obesity (SURMOUNT-1, 72 weeks): mean 22.5% body-weight reduction at the highest dose. Retatrutide in adults with obesity and knee osteoarthritis (TRIUMPH-4, 68 weeks): mean 28.7% body-weight reduction at the 12 mg dose. Tirzepatide in adults with type 2 diabetes (SURPASS-2, 40 weeks): A1C reduction of approximately 2.4 percentage points at the highest dose. Retatrutide in adults with type 2 diabetes (TRANSCEND-T2D-1, 40 weeks): A1C reduction of 1.7 to 2.0 percentage points across doses.
These numbers suggest retatrutide may produce somewhat deeper weight loss than tirzepatide and somewhat shallower A1C reduction in T2D-only populations. They do not prove either claim. Different populations, dose-titration schedules, and trial durations all influence the result. For the deeper comparison see our retatrutide vs tirzepatide overview.
Practical Differences That Affect Patients
Beyond the trial data, four practical differences matter for someone trying to make sense of the two drugs.
Availability. Mounjaro and Zepbound are approved and available in the U.S. (subject to insurance coverage and supply). Retatrutide is not approved and is not commercially available under any name. For more on current and future access, see how to get retatrutide.
Insurance coverage. Tirzepatide coverage is increasingly common in the U.S., though formulary specifics vary widely. Retatrutide coverage does not yet exist because the drug is not yet a marketed product.
Cost. Tirzepatide list prices in the U.S. are publicly known; out-of-pocket costs vary substantially based on insurance and manufacturer programs. Retatrutide pricing has not been disclosed and will not be set until closer to approval. Our retatrutide cost predictions page summarizes what is currently inferable.
Side effects. Both drugs produce gastrointestinal adverse events (nausea, diarrhea, vomiting) typical of incretin-based therapies, concentrated during dose escalation. Retatrutide trials have also reported small rates of dysesthesia (abnormal skin sensations), which is a signal worth tracking but has not changed the overall benefit-risk picture so far.
What ‘Mounjaro for Weight Loss’ Actually Means
When someone says ‘Mounjaro for weight loss,’ they are usually describing one of three situations.
Off-label tirzepatide. Some patients are prescribed Mounjaro (the T2D brand) for weight management. This is off-label use of the same molecule that is FDA-approved as Zepbound for chronic weight management.
Compounded tirzepatide. During periods of supply shortage, compounded versions of tirzepatide were available through compounding pharmacies. The FDA has progressively narrowed the conditions under which compounded tirzepatide is permissible, and the regulatory picture has shifted multiple times in recent years.
Confusion with Zepbound. Sometimes ‘Mounjaro for weight loss’ just means Zepbound. The molecule is the same, but the prescribing pathway, brand, and labeling differ.
None of these scenarios involves retatrutide. Retatrutide cannot be prescribed for weight loss — or anything else — until it is FDA-approved.
Bottom Line
Mounjaro is tirzepatide, a dual GLP-1/GIP agonist, approved and available today. It is also sold as Zepbound for chronic weight management — same molecule, different brand and label.
Retatrutide is a triple GLP-1/GIP/glucagon agonist, investigational, not yet approved. It does not yet have a brand name and cannot legally be prescribed for any indication.
They are made by the same company (Eli Lilly). They treat overlapping conditions. Their mechanisms are related but not identical. They are not the same drug, and confusion between them is one of the most common mistakes in retatrutide-related searches and conversations. The cleanest way to keep them straight is to remember the receptor count: Mounjaro/Zepbound activates two receptors; retatrutide activates three.
Stay Updated
If you’d like to be notified the moment retatrutide is approved (and what its actual U.S. brand name will be), join our retatrutide updates list. One email per major milestone, no marketing.
Disclaimer
Retatrutide is an investigational medication and is not approved by the FDA for any indication. Mounjaro and Zepbound are FDA-approved tirzepatide products. This post is educational and should not be interpreted as medical advice or as a recommendation for any specific treatment. For information about how our content is sourced and reviewed, see our editorial policy and medical review policy.
FAQ SECTION
Are Mounjaro and Zepbound the same drug?
Yes — both contain the same active ingredient, tirzepatide. Mounjaro is the brand name for tirzepatide approved for type 2 diabetes. Zepbound is the brand name for the same molecule approved for chronic weight management in adults with obesity. The molecule is identical; the brands and indications differ for regulatory and commercial reasons.
Will retatrutide replace Mounjaro?
Not in the way the question implies. Even if retatrutide is approved, Mounjaro and Zepbound are likely to remain on the market. Eli Lilly has indicated that retatrutide is intended as a portfolio addition rather than a tirzepatide replacement. Clinical decisions between the two will depend on individual patient factors, head-to-head data from TRIUMPH-5, and payer formulary positioning.
Can I get retatrutide instead of Mounjaro right now?
No. Retatrutide is investigational and cannot legally be prescribed for any indication. The only ways to access retatrutide today are through participation in an active clinical trial (eligibility is restricted) or — until approval — not at all. See our overview of whether you can get retatrutide now.
Does retatrutide work the same way as Mounjaro?
Partially. Both drugs activate the GLP-1 and GIP receptors. Retatrutide additionally activates the glucagon receptor, which Mounjaro does not. Glucagon receptor activation contributes to increased energy expenditure and lipid metabolism, which is one of the proposed reasons retatrutide has produced deeper weight loss than tirzepatide in trials to date.
Why does Eli Lilly make so many similar drugs?
Eli Lilly’s incretin portfolio reflects a deliberate strategy of developing multiple drugs with overlapping but distinct mechanisms — single, dual, and triple agonists; injectable and oral formulations. The portfolio approach lets Lilly compete across different patient populations, treatment preferences, and payer environments. Tirzepatide, retatrutide, and orforglipron each occupy different positions in that broader portfolio.
